Hims & Hers' AI-First Weight Loss Bet Faces Its First Earnings Test

Hims & Hers Health Inc (HIMS) reports Q2 2026 earnings after market close on August 10, 2026, with analysts expecting a loss of $0.07 per share—a sharp reversal from the $0.17 profit posted in the same quarter last year. The report comes at a critical juncture for the telehealth platform, following a disastrous Q1 miss that saw the company report a $0.18 loss versus a $0.04 profit estimate, triggering a 550% negative surprise and raising questions about the sustainability of its growth trajectory.

Part 1: Earnings Preview

Hims & Hers Health operates a direct-to-consumer telehealth platform offering personalized treatments across categories including sexual health, hair loss, dermatology, mental health, and weight management. The company has gained attention for its subscription-based model and proprietary product offerings that command higher margins.

For Q2 2026, Wall Street expects HIMS to report a loss of $0.07 per share when it announces results after the close on August 10. Estimates range widely from a loss of $0.16 to a loss of just $0.01, reflecting significant uncertainty among the three analysts covering this release. The most recently reported quarter (Q1 2026) delivered a loss of $0.18 per share, badly missing the $0.04 profit estimate. Year-over-year, the expected $0.07 loss represents a dramatic 141% decline from the $0.17 profit reported in Q2 2025, underscoring the sharp deterioration in profitability.

Three key themes define this earnings story:

Regulatory headwinds and compliance costs — Management commentary on regulatory challenges will be critical, as increased scrutiny of telehealth platforms and prescription practices has likely pressured margins and operational flexibility. Investors need clarity on how the company is navigating this environment and what ongoing compliance investments mean for near-term profitability.

Margin pressure from product mix shifts — The proportion of revenue driven by higher-margin proprietary products versus third-party offerings will be closely watched. Any shift away from proprietary treatments could explain the earnings deterioration and signal challenges in maintaining the company's differentiated value proposition.

Guidance reset and path back to profitability — After the Q1 disaster, investors are looking for a credible roadmap. Quarterly guidance trends, commentary on telehealth adoption rates, and penetration into new categories like weight loss will determine whether HIMS can restore confidence in its growth trajectory.

Analyst sentiment remains cautious heading into the print. While some see the current weakness as a temporary reset, others point to structural challenges in the telehealth model that may take multiple quarters to resolve. The wide estimate range reflects this uncertainty, with bears modeling continued losses and bulls expecting a quick return to profitability by Q3.

Part 2: Historical Earnings Performance

HIMS has delivered a volatile earnings track record over the past four quarters, with results swinging from significant beats to catastrophic misses. In Q2 2025, the company reported $0.17 per share against a $0.18 estimate, a modest 5.56% miss. The following quarter (Q3 2025) saw HIMS meet expectations exactly at $0.09 per share. Q4 2025 marked a dramatic turnaround with $0.07 reported versus $0.02 estimated, delivering a 250% beat that briefly restored investor confidence.

However, the most recent quarter (Q1 2026) shattered that optimism. HIMS reported a loss of $0.18 per share against expectations for a $0.04 profit, resulting in a staggering 550% negative surprise. This represents the worst miss in the company's recent history and a complete reversal from the prior quarter's strong performance.

The pattern reveals no consistent trend—HIMS has alternated between beats, in-line results, and misses with no predictable cadence. The magnitude of the Q1 miss suggests operational or structural issues rather than minor execution stumbles, making the upcoming Q2 report critical for determining whether the company can stabilize or if further deterioration lies ahead.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

HIMS reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 2.20% and Day +1 move of 9.60%. The most recent earnings (May 2026) saw a modest 3.08% gain on Day 0 followed by a sharp 14.10% decline on Day +1 as the market absorbed the disappointing results. The prior quarter (February 2026) exhibited relatively muted Day 0 movement but still delivered a 22.32% drop on Day +1, highlighting how after-hours results can trigger outsized next-day reactions.

The largest single-day move came in May 2025, when the stock surged 18.12% on Day +1 following a strong beat. Conversely, the February 2025 report triggered a 22.32% decline on Day +1 despite a 4.12% pre-earnings gain. The average Day +1 range of 14.71% suggests investors should prepare for substantial volatility regardless of direction. Given the recent track record of disappointing results and the wide estimate range for Q2, the risk of another double-digit decline appears elevated if HIMS fails to deliver a credible turnaround story.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 12.32% (±$3.89) for the week of August 14 expiration, which sits above the historical Day 0 average of 2.20% but below the Day +1 average of 9.60%. This suggests options traders are anticipating volatility in line with recent history, though the 12.32% implied move falls short of the extreme reactions seen in February and May 2026 when Day +1 moves exceeded 14% and 22% respectively.

Part 3: What Analysts Are Saying

Analyst sentiment on HIMS remains cautious, with the consensus rating at 3.33 (between Hold and Buy) based on 15 analysts. The breakdown shows 2 Strong Buys, 1 Moderate Buy, 12 Holds, and 0 Sells, reflecting a largely neutral stance with a small bullish minority. Notably, sentiment has improved over the past month, with one analyst upgrading from Strong Sell, though the overall posture remains defensive.

The average price target of $29.77 sits 5.8% below the current price of $31.59, suggesting analysts see limited upside and potential downside risk in the near term. Price targets range from a low of $21.00 (34% downside) to a high of $40.00 (27% upside), reflecting the wide dispersion of views on the company's prospects. The fact that the mean target implies downside is particularly notable given that analyst targets typically skew optimistic.

The shift from one Strong Sell to a more neutral stance indicates some analysts believe the worst may be priced in after the Q1 collapse, but the heavy concentration of Hold ratings—12 of 15 analysts—signals that most are taking a wait-and-see approach. The consensus appears to be that HIMS needs to prove it can return to profitability and stabilize its business model before warranting more aggressive buy recommendations.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 56%, down sharply from 72% Buy a month ago, indicating weakening momentum as earnings approach. The signal also deteriorated from 24% Buy just last week, suggesting recent price action has turned more cautious. This declining trend in technical strength mirrors the fundamental uncertainty heading into the Q2 report.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is mixed, with the stock showing some positive technical characteristics but lacking conviction
• Medium-term (100% Buy): Strong buy signal suggests the intermediate-term trend remains intact despite recent weakness, providing some technical support
• Long-term (50% Buy): Moderate buy signal reflects a balanced longer-term technical picture without clear directional bias

The trend is characterized as Weak and Weakening, indicating deteriorating technical conditions as the stock approaches earnings. This suggests the technical setup is losing strength at a critical juncture.

From a moving average perspective, HIMS trades at $31.59, positioned above all major moving averages including the 5-day ($31.18), 10-day ($29.52), 20-day ($31.32), 50-day ($31.44), 100-day ($27.84), and 200-day ($29.73). While this above-average positioning typically signals technical strength, the stock is trading very close to its 20-day and 50-day averages, suggesting it's testing key support levels. The weakening technical opinion combined with proximity to these moving averages creates a precarious setup—a disappointing earnings report could quickly push the stock below these support levels and trigger further technical selling. Conversely, a positive surprise would have clear upside runway given the stock's position above longer-term averages.

Key technical levels to watch include the 50-day moving average at $31.44 and 20-day at $31.32, both sitting just below the current price and representing immediate support. A break below these levels on disappointing results could trigger a test of the 10-day average at $29.52. On the upside, the stock has room to run toward the $35-40 range if results surprise positively, given the distance from recent highs. Overall, the technical setup is cautionary heading into earnings—the weakening momentum, deteriorating opinion signal, and proximity to key support levels suggest the path of least resistance may be lower if HIMS fails to deliver a credible turnaround story.